phosphorylcholine has been researched along with Arteriosclerosis, Coronary in 10 studies
Phosphorylcholine: Calcium and magnesium salts used therapeutically in hepatobiliary dysfunction.
phosphocholine : The phosphate of choline; and the parent compound of the phosphocholine family.
| Excerpt | Relevance | Reference |
|---|---|---|
| "The ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial was a randomized controlled study of zotarolimus-eluting, phosphorylcholine-coated, cobalt-alloy stents for the treatment of de novo coronary lesions compared with using PES for the same treatment." | 9.14 | Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. ( Ako, J; Fitzgerald, PJ; Hasegawa, T; Honda, Y; Kandzari, DE; Leon, MB; Miyazawa, A; Sakurai, R; Tsujino, I; Waseda, K; Yock, PG, 2009) |
| "Low anti-phosphorylcholine (PC) IgM plasma levels have been associated with increased incidence of adverse events in coronary artery disease (CAD)." | 7.81 | Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease. ( Akhavanpoor, M; Buss, SJ; Conradson, G; Doesch, AO; Domschke, G; Erbel, C; Gitsioudis, G; Gleissner, CA; Haeussler, J; Hofmann, NP; Katus, HA; Korosoglou, G; Linden, F, 2015) |
| "The ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial was a randomized controlled study of zotarolimus-eluting, phosphorylcholine-coated, cobalt-alloy stents for the treatment of de novo coronary lesions compared with using PES for the same treatment." | 5.14 | Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease. ( Ako, J; Fitzgerald, PJ; Hasegawa, T; Honda, Y; Kandzari, DE; Leon, MB; Miyazawa, A; Sakurai, R; Tsujino, I; Waseda, K; Yock, PG, 2009) |
| "Studies have reported an association between low levels of natural immunoglobulin M antibodies against phosphorylcholine(IgM anti-PC) and worse prognosis in patients with coronary artery disease (CAD)." | 3.91 | IgM antibodies against phosphorylcholine measured early after acute ST-elevation myocardial infarction in relation to atherosclerotic disease burden and long-term clinical outcome. ( Aksnes, TA; Andersen, GØ; Arnesen, H; Eritsland, J; Knudsen, EC; Seljeflot, I, 2019) |
| "Low anti-phosphorylcholine (PC) IgM plasma levels have been associated with increased incidence of adverse events in coronary artery disease (CAD)." | 3.81 | Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease. ( Akhavanpoor, M; Buss, SJ; Conradson, G; Doesch, AO; Domschke, G; Erbel, C; Gitsioudis, G; Gleissner, CA; Haeussler, J; Hofmann, NP; Katus, HA; Korosoglou, G; Linden, F, 2015) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (10.00) | 18.2507 |
| 2000's | 6 (60.00) | 29.6817 |
| 2010's | 3 (30.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Knudsen, EC | 1 |
| Seljeflot, I | 1 |
| Aksnes, TA | 1 |
| Eritsland, J | 1 |
| Arnesen, H | 1 |
| Andersen, GØ | 1 |
| Gleissner, CA | 1 |
| Erbel, C | 1 |
| Haeussler, J | 1 |
| Akhavanpoor, M | 1 |
| Domschke, G | 1 |
| Linden, F | 1 |
| Doesch, AO | 1 |
| Conradson, G | 1 |
| Buss, SJ | 1 |
| Hofmann, NP | 1 |
| Gitsioudis, G | 1 |
| Katus, HA | 1 |
| Korosoglou, G | 1 |
| Waseda, K | 1 |
| Miyazawa, A | 1 |
| Ako, J | 1 |
| Hasegawa, T | 1 |
| Tsujino, I | 1 |
| Sakurai, R | 2 |
| Yock, PG | 2 |
| Honda, Y | 2 |
| Kandzari, DE | 1 |
| Leon, MB | 1 |
| Fitzgerald, PJ | 2 |
| von Birgelen, C | 1 |
| Basalus, MW | 1 |
| Swanson, N | 1 |
| Javed, Q | 1 |
| Hogrefe, K | 1 |
| Gershlick, A | 1 |
| Babapulle, MN | 1 |
| Eisenberg, MJ | 1 |
| Shinozaki, N | 1 |
| Yokoi, H | 1 |
| Iwabuchi, M | 1 |
| Nosaka, H | 1 |
| Kadota, K | 1 |
| Mitsudo, K | 1 |
| Nobuyoshi, M | 1 |
| Hongo, Y | 1 |
| Yamasaki, M | 1 |
| Bonneau, HN | 1 |
| Cutlip, D | 1 |
| Popma, JJ | 1 |
| Zimetbaum, P | 1 |
| Fajadet, J | 1 |
| Kuntz, RE | 1 |
| Wijns, W | 1 |
| Bhakdi, S | 1 |
| Torzewski, M | 1 |
| Klouche, M | 1 |
| Hemmes, M | 1 |
| Grenadier, E | 1 |
| Roguin, A | 1 |
| Hertz, I | 1 |
| Peled, B | 1 |
| Boulos, M | 1 |
| Nikolsky, E | 1 |
| Amikam, S | 1 |
| Kerner, A | 1 |
| Cohen, S | 1 |
| Beyar, R | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| A Randomized, Controlled Trial of the Medtronic Endeavor Drug (ABT-578) Eluting Coronary Stent System Versus the Taxus Paclitaxel-Eluting Coronary Stent System in De Novo Native Coronary Artery Lesions[NCT00217269] | 1,548 participants (Actual) | Interventional | 2005-04-30 | Completed | |||
| [NCT00973375] | 30 participants (Anticipated) | Observational | 2009-05-31 | Recruiting | |||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
1 review available for phosphorylcholine and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Coated stents for the prevention of restenosis: Part II.
Topics: Angioplasty, Balloon, Coronary; Anticoagulants; Antineoplastic Agents; Clinical Trials as Topic; Coa | 2002 |
4 trials available for phosphorylcholine and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Topics: Aged; Alloys; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coated Materials, Biocompatible | 2009 |
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Topics: Aged; Alloys; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coated Materials, Biocompatible | 2009 |
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Topics: Aged; Alloys; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coated Materials, Biocompatible | 2009 |
Intravascular ultrasound results from the ENDEAVOR IV trial: randomized comparison between zotarolimus- and paclitaxel-eluting stents in patients with coronary artery disease.
Topics: Aged; Alloys; Angioplasty, Balloon, Coronary; Cardiovascular Agents; Coated Materials, Biocompatible | 2009 |
Initial and follow-up results of the BiodivYsio phosphorylcholine coated stent for treatment of coronary artery disease.
Topics: Aged; Coated Materials, Biocompatible; Coronary Angiography; Coronary Artery Disease; Coronary Reste | 2005 |
Detailed intravascular ultrasound analysis of Zotarolimus-eluting phosphorylcholine-coated cobalt-chromium alloy stent in de novo coronary lesions (results from the ENDEAVOR II trial).
Topics: Chromium Alloys; Coated Materials, Biocompatible; Cohort Studies; Coronary Artery Disease; Coronary | 2007 |
Stenting very small coronary narrowings (< 2 mm) using the biocompatible phosphorylcholine-coated coronary stent.
Topics: Adult; Aged; Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Coronary Artery Diseas | 2002 |
5 other studies available for phosphorylcholine and Arteriosclerosis, Coronary
| Article | Year |
|---|---|
IgM antibodies against phosphorylcholine measured early after acute ST-elevation myocardial infarction in relation to atherosclerotic disease burden and long-term clinical outcome.
Topics: Aged; Antibodies, Anti-Idiotypic; Atherosclerosis; Coronary Artery Disease; Female; Follow-Up Studie | 2019 |
Low levels of natural IgM antibodies against phosphorylcholine are independently associated with vascular remodeling in patients with coronary artery disease.
Topics: Aged; Autoantibodies; Biomarkers; Chi-Square Distribution; Coronary Angiography; Coronary Artery Dis | 2015 |
On the loss of the phosphorylcholine-based DES coating on the abluminal surface of Endeavor stents.
Topics: Angioplasty, Balloon, Coronary; Coated Materials, Biocompatible; Coronary Artery Disease; Drug-Eluti | 2010 |
Human internal mammary artery organ culture model of coronary stenting: a novel investigation of smooth muscle cell response to drug-eluting stents.
Topics: Cell Division; Coated Materials, Biocompatible; Coronary Artery Disease; Drug Delivery Systems; Graf | 2002 |
Complement and atherogenesis: binding of CRP to degraded, nonoxidized LDL enhances complement activation.
Topics: C-Reactive Protein; Calcium; Cholesterol, LDL; Complement Activation; Complement C3; Complement Memb | 1999 |